Nasal spray of an IgM‐like ACE2 fusion protein HH‐120 accelerates SARS‐CoV‐2 clearance: A single‐center propensity score‐matched cohort study

• Published in: Journal of medical virology Vol. 95; no. 5; pp. e28805 - n/a
• Main Authors: Song, Rui, Chen, Xiaoyou, Li, Baoliang, Zhang, Hongbin, Guo, Xiaodi, Liu, Zhe, Zou, Liangfeng, Liang, Xiao, Lei, Cong, Mao, Fengfeng, Sui, Jianhua, Li, Wenhui, Jin, Ronghua
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.05.2023
• Subjects: ACE2; Adverse events; Angiotensin-Converting Enzyme 2; Antiviral drugs; Clinical trials; Cohort analysis; Cohort Studies; Coronaviruses; COVID-19; Disease transmission; Effectiveness; Fusion protein; Health services; HH‐120; Humans; Immunoglobulin M; nasal spray; Nasal Sprays; Propensity Score; propensity score matching; Proteins; Safety; SARS-CoV-2; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Subgroups; viral clearance time; Viral diseases; Virology; viral clearance time; SARS-CoV-2; propensity score matching; HH-120; nasal spray

HH‐120, a recently developed IgM‐like ACE2 fusion protein with broad‐spectrum neutralizing activity against all ACE2‐utilizing coronaviruses, has been developed as a nasal spray for use as an early treatment agent to reduce disease progression and airborne transmission. The objective of this study w...